Cargando…
Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force
BACKGROUND: Many patients with rare diseases are still lacking a timely diagnosis and approved therapies for their condition despite the tremendous efforts of the research community, biopharmaceutical, medical device industries, and patient support groups. The development of clinical research networ...
Autores principales: | Nabbout, Rima, Zanello, Galliano, Baker, Dixie, Black, Lora, Brambilla, Isabella, Buske, Orion J., Conklin, Laurie S., Davies, Elin Haf, Julkowska, Daria, Kim, Yeonju, Klopstock, Thomas, Nakamura, Harumasa, Nielsen, Kim G., Pariser, Anne R., Pastor, Jose Carlos, Scarpa, Maurizio, Smith, Maureen, Taruscio, Domenica, Groft, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169162/ https://www.ncbi.nlm.nih.gov/pubmed/37161573 http://dx.doi.org/10.1186/s13023-023-02650-4 |
Ejemplares similares
-
Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients
por: Zanello, Galliano, et al.
Publicado: (2022) -
Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective
por: Austin, Christopher P., et al.
Publicado: (2017) -
Essential list of medicinal products for rare diseases: recommendations from the IRDiRC Rare Disease Treatment Access Working Group
por: Gahl, William A., et al.
Publicado: (2021) -
Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures
por: Morel, Thomas, et al.
Publicado: (2017) -
The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies
por: Beaverson, Katherine L., et al.
Publicado: (2023)